nevirapine has been researched along with Tuberculosis, Multidrug-Resistant in 3 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we aimed to quantify nevirapine and LPV/r drug-drug interaction effects on bedaquiline and M2 in patients co-infected with HIV and multidrug-resistant tuberculosis (MDR-TB) using population pharmacokinetic (PK) analysis and compare these with model-based predictions from single-dose studies in subjects without TB." | 1.46 | Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. ( Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM, 2017) |
| "Bedaquiline is a new anti-TB drug, which is metabolized by cytochrome P450 (CYP) 3A4." | 1.43 | Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. ( Conradie, F; Hughes, J; Maartens, G; McIlleron, H; Pandie, M; Siwendu, S; Variava, E; Wiesner, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Daftary, A | 1 |
| Orrell, C | 1 |
| Dooley, KE | 1 |
| Rivet Amico, K | 1 |
| Friedland, G | 1 |
| Pandie, M | 2 |
| Wiesner, L | 1 |
| McIlleron, H | 1 |
| Hughes, J | 1 |
| Siwendu, S | 1 |
| Conradie, F | 1 |
| Variava, E | 1 |
| Maartens, G | 2 |
| Brill, MJ | 1 |
| Svensson, EM | 1 |
| Karlsson, MO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056] | 360 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for nevirapine and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Substitution; Fem | 2019 |
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Combinations; Drug Interactions; Drug Monitorin | 2016 |
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antitubercular Agents; Diarylquinolines | 2017 |